预测直接口服抗凝药患者大胃肠道出血风险的新模型
该评分包含12个因素,AUC为0.77(95%CI 0.74-0.81),优于HAS-BLED评分(0.69;95%CI 0.65-0.72)和New评分(0.65;95%CI 0.61-0.68)。
要点
- Alfalfa-DOAC-GIB评分包含12个因素,AUC 0.77,预测价值优于HAS-BLED和New评分。
- 年龄≥65岁、饮酒、消化性溃疡史、大出血史、肝肾功能异常、癌症等为独立危险因素。
- 联用抗血小板药或NSAID增加出血风险,联用胃肠道保护剂为保护因素。
核心结论
- 基于12个因素构建的Alfalfa-DOAC-GIB评分对DOACs患者胃肠道出血的预测价值优于HAS-BLED评分和New评分。
主要发现
- 多因素分析显示年龄≥65岁、饮酒、消化性溃疡史、大出血史、肝或肾功能异常、癌症、血小板计数<100×10^9/L、贫血、联用抗血小板药或NSAID为GIB独立危险因素。
- 联用胃肠道保护剂为保护因素。
- Alfalfa-DOAC-GIB评分AUC为0.77(95%CI 0.74-0.81),高于HAS-BLED评分(0.69;95%CI 0.65-0.72)和New评分(0.65;95%CI 0.61-0.68)。
关键数值与推荐
- Alfalfa-DOAC-GIB评分包含12个因素:年龄≥65岁、饮酒、消化性溃疡史、大出血史、肝或肾功能异常、癌症、血小板计数<100×10^9/L、贫血、联用抗血小板药、联用NSAID、联用胃肠道保护剂(保护因素)。
临床怎么用
- 该评分可用于接受达比加群或利伐沙班治疗患者的胃肠道出血风险评估,辅助临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to identify factors associated with gastrointestinal bleeding (GIB) in patients on direct oral anticoagulants (DOACs) and develop a risk score that would provide an effective tool for the clinical assessment of GIB. METHODS: This was a multicentre retrospective analysis of clinical and follow-up data of patients treated with DOACs. The score was developed through logistic regression. The performance of score was evaluated using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity and Hosmer-Lemeshow test. RESULTS: The 11 903 patients had a mean age of 65.1 years. In multivariate analysis, age ≥65 years, alcohol use, history of peptic ulcer, history of major bleeding, abnormal liver function or renal function, cancer, platelet count <100 × 109 /L, anaemia, and concurrent antiplatelet agent or non-steroidal anti-inflammatory drug treatment were independent risk factors for GIB, and concurrent treatment with gastrointestinal protective agents were a protective factor. The Alfalfa-DOAC-GIB score was constructed using these 12 factors. The AUC of the Alfalfa-DOAC-GIB score was 0.77 (95% CI 0.74-0.81), which was higher than that of the HAS-BLED score (0.69; 95% CI 0.65-0.72) and the New score (0.65; 95% CI 0.61-0.68). CONCLUSIONS: Based on 12 factors, we developed a gastrointestinal bleeding risk score. The newly developed Alfalfa-DOAC-GIB score has better predictive value than the HAS-BLED score and the New score, and might be an effective tool to help reduce the occurrence of GIB in patients using DOACs.
引用
- Lv M, Jiang S, Wu T, et al. A new model to predict the risk of major gastrointestinal bleeding in patients on direct oral anticoagulants (dabigatran and rivaroxaban). Br J Clin Pharmacol. 2022. PMID: 35971682. doi:10.1111/bcp.15491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。